Abstract 787P
Background
The conventional classification tools for endometrial carcinoma (EC) is tiresome, including DNA sequencing, IHC or PCR-CE. Large NGS panels are used to simplify test but costly. Here, we propose a concise NGS panel for economically classifying EC.
Methods
Retrospectively enrolled EC cases of hysterectomy with bilateral salpingo-oophorectomy from Fudan University Shanghai Cancer Center from 2020 to 2022 were assessed. A 46-gene NGS Panel was used to identify POLE exonuclease domain mutations, microsatellite instability-high (MSI-H), TP53 mutations, and other clinically valuable targets.
Results
Tumor tissue samples of 331 EC patients were evaluated. The median age of patients was 55 years (range, 49-62), and 284 (85.8%) cases were endometrioid endometrial carcinoma. Patients in stage IA and IB EC were 204 (61.6%) and 52 (15.7%), respectively. The median follow-up time was 18.5 months (n=303). According to WHO classification criteria, patients were stratified into POLE mut (n=47; 14.2%), MMRd (n=79; 23.9%), NSMP (n=148; 44.7%) and p53 abn (n=57; 17.2%), whose prognosis was consistent with previous studies, POLE mut with most favorable prognosis and p53 abn with the worst. NGS reached 91.8% (n=269) concordance with IHC when detecting MMRd. The 24 inconsistent samples were validated by PCR, of which 17 (70.8%) were consistent between PCR and NGS. The concordance of NGS and IHC in detecting p53 was 65.0% (n=201), but patients detected by NGS alone had significantly worse prognosis than those detected by IHC alone, implying higher accuracy of the panel. Given NGS panel performance, particularly in detecting MMRd and p53 abn, our panel provided a reliable EC classification approach. In addition, the most frequent genetic alterations detected in at least 20% of patients were PTEN (83.4%), PIK3CA (59.2%), ARID1A (58.6%), TP53 (29.3%), CTNNB1 (27.8%), and KRAS (23.6%), which might guide the following treatment.
Conclusions
Our study demonstrates that the concise NGS panel is an effective “one-stop” strategy to precisely classify EC with high clinical availability. Further follow-up data are needed to testify to the effect of the classification on the prognosis of different adjuvant therapies or rare pathological subtypes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11